Circulating levels of GDF15 in patients with myalgic encephalomyelitis/chronic fatigue syndrome.
Journal of translational medicine
MetadataShow full item record
Melvin, A., Lacerda, E., Dockrell, H., O'Rahilly, S., & Nacul, L. (2019). Circulating levels of GDF15 in patients with myalgic encephalomyelitis/chronic fatigue syndrome.. Journal of translational medicine, 17 (1), 409. https://doi.org/10.1186/s12967-019-02153-6
Background: Myalgic encephalomyelitis/Chronic fatigue syndrome (ME/CFS) is a debilitating condition characterised by fatigue and post-exertional malaise. Its pathogenesis is poorly understood. GDF15 is a circulating protein secreted by cells in response to a variety of stressors. The receptor for GDF15 is expressed in the brain, where its activation results in a range of responses. Among the conditions in which circulating GDF15 levels are highly elevated are mitochondrial disorders, where early skeletal muscle fatigue is a key symptom. We hypothesised that GDF15 may represent a marker of cellular stress in ME/CFS. Methods: GDF15 was measured in serum from patients with ME/CFS (n=150; 100 with mild/moderate and 50 with severe symptoms), “healthy volunteers” (n=150) and a cohort of patients with multiple sclerosis (n=50). Results: Circulating GDF15 remained stable in a subset of ME/CFS patients when sampled on two occasions ~7 months (IQR 6.7-8.8) apart, 720 pg/ml (95% CI=625-816) vs 670 pg/ml (95% CI=598-796), P=0.5. GDF15 levels were 491 pg/ml in controls (95% CI= 429-553), 546 pg/ml (95% CI= 478 to 614) in MS patients, 560 pg/ml (95% CI= 502 to 617) in mild/moderate ME/CFS patients and 602 pg/ml (95% CI=531 to 674) in severely affected ME/CFS patients. Accounting for potential confounders, severely affected ME/CFS patients had GDF15 concentrations that were significantly increased compared to healthy controls (P = 0.01). GDF15 levels were positively correlated (P=0.026) with fatigue scores in ME/CFS. Conclusions: Severe ME/CFS is associated with increased levels of GDF15, a circulating biomarker of cellular stress that appears which stable over several months.
Wellcome Trust (214274/Z/18/Z)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Embargo Lift Date
External DOI: https://doi.org/10.1186/s12967-019-02153-6
This record's URL: https://www.repository.cam.ac.uk/handle/1810/299333
All rights reserved